Rheumatoid Arthritis Clinical Trial
Official title:
A Phase II, Randomised, Double-blind, International, Multicentre, Placebo-controlled, Dose-ranging, Parallel-group Study to Evaluate the Efficacy and Safety of Orally Administered Rob 803 When Added to Stable Methotrexate
The primary objective of this study is to evaluate the efficacy (ACR20) of Rob 803 administered orally once daily for 12 weeks in combination with a stable dose of methotrexate in subjects with moderate or severe active RA.
Rheumatoid arthritis (RA) is a common, chronic, disabling systemic autoimmune disease in
which inflammation of the joint lining (synovium) occurs when the body's tissues are
attacked by the immune system. The joint inflammation begins in the synovium and slowly
destroys the cartilage, narrowing the joint and eventually damaging the bone. A large amount
of inflammatory mediators or rheumatoid factors are synthesised in the joint which
accelerate proliferation and differentiation of immune cells further to amplify the
autoimmune reaction. A widely accepted model has emerged in which the presence of
inflammation in established RA is driven by interactions between T cells, macrophages, and
fibroblasts in an abnormal microenvironment.
Rheumatoid arthritis has an annual incidence of approximately 0.2 per 1000 in males and 0.4
per 1000 in females. In general, higher rates have been reported in the USA than in European
populations. The incidence of RA increases with age until the mid 70s. A prevalence of
0.5-1% is reported in diverse populations world-wide.
Treatments for RA focus on relieving pain, reducing inflammation, slowing or stopping joint
damage, and improving patients' well being and ability to function. Current therapies
include non-steroidal anti-inflammatory drugs (NSAIDs) which target the clinical features of
the disease to alleviate the pain and swelling that accompany RA, disease-modifying
anti-rheumatic drugs (DMARDs) which target the actual cause of the disease and biological
agents which are genetically engineered to target and modify the autoimmune response.
Non-steroidal anti-inflammatory drugs are effective in managing the symptoms of RA, but are
limiting as they cannot suppress progression of the disease. First line treatment on
confirmation of RA is the use of DMARDs, supported by pain relief medication.
Biologic agents (TNF antagonists, anti B-cell agents and anti-interleukins) have proven
effective in RA symptoms management. TNF antagonists have become an important therapeutic
option in the treatment of advanced RA.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |